Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Protein Phosphatase 2A - Pipeline Review, H1 2017'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

The report 'Protein Phosphatase 2A - Pipeline Review, H1 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Alzheimer's Disease, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Conjunctivitis, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Endometrial Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Prostate Cancer, Renal Cell Carcinoma, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, T-Cell Leukemia, Ulcerative Colitis, Uveal Melanoma and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Ampio Pharmaceuticals Inc
Bristol-Myers Squibb Company
Cyano Biotech GmbH
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
Signum Biosciences Inc
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
Drugs to Activate PP2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-1154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings
Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Feb 10, 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer
Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer